IUD for Perimenopause Symptoms and HRT

A woman can be eight months postpartum, exhausted, still bleeding on an unpredictable schedule, and nobody, not even her doctor, can say for certain whether her body is recovering from childbirth or already sliding into perimenopause, the years of hormonal turbulence before menopause. That ambiguity, it turns out, is not a gap in medicine. It is the whole terrain. In this conversation, OB-GYN Dr. Fran Haydanek, who also hosts the podcast I Did My Own Research, walks Dr. Mary Claire Haver through the signals that actually matter when a woman's cycle changes, and the ones that get dismissed.

When a Period Stops Being Just a Period

Haydanek starts with a baseline: a period every 28 days, lasting about three days, manageable with a few tampons, is the expected pattern for a woman without other conditions (00:53). What she watches for in perimenopause is change in either direction, longer or shorter cycles, and especially heavier bleeding. Her bright line is specific: soaking a super tampon every hour, or bleeding for seven days instead of three, is a signal to look for fibroids, polyps, or cancer, not just hormones spacing out (01:32). The stakes are sharper for women with PCOS, polycystic ovary syndrome, a hormonal condition marked by irregular ovulation. Haydanek says patients with PCOS have five times the risk of endometrial cancer before menopause, because chronic anovulation (not releasing an egg) lets the uterine lining build up unchecked (01:54). Any bleeding after twelve full months without a period, she adds, is a 100 percent reason to book a problem visit for an ultrasound and likely a tissue biopsy (03:15).

She is equally blunt about what a normal lab result should and should not settle.

No one should be ordering blood tests that they don't know how to interpret.
— Dr. Fran Haydanek (03:49)

Her point is that a clinician who orders an estrogen level to appease a patient, without knowing how to read it in context, can leave a real problem unaddressed. A second opinion, she says, is always valid.

That same uncertainty shows up in a demographic shift: the birth rate for women aged 40 to 44 is now 12.7 per 1,000, the highest since 1965, meaning one in 24 American births is to a woman in that age band (05:48). Many of these women are postpartum and sliding into perimenopause at the same time, and Haydanek treats the overlap as both, not either/or, tailoring care to how recently someone gave birth and whether she is still breastfeeding (06:12). The same caution applies to the so called tired mom trap, where exhaustion, anxiety, and poor sleep in a woman's 40s get blamed on her schedule. Haydanek checks for sleep apnea and a low ferritin level (a measure of iron storage), both of which can mimic perimenopausal symptoms like hair loss and restless legs (09:38).

Contraception timing is another place where confusion causes real risk. Ovulation can still happen in perimenopause, so Haydanek tells patients not to treat the transition itself as birth control, and is equally direct that hormone therapy for symptoms is not a contraceptive: "It is not birth control. It is not a high enough dose to suppress ovulation" (12:45). The practical fix she reaches for constantly is an intrauterine device, or IUD. It thins the uterine lining, which eases heavy perimenopausal bleeding, it protects the uterus from the cancer risk of unopposed estrogen therapy, and it prevents pregnancy, three functions in one device (13:58). For symptoms beyond bleeding, she lays out a menu: estrogen patches paired with a progestin (micronized progesterone, an IUD, or another form) to protect the uterus, plus non-hormonal options like SSRIs, gabapentin, or the newer medication Veozah for patients who cannot or do not want hormones (15:49).

PCOS itself does not end at menopause, and Haydanek wants that remembered. "PMOS, I want people to remember, is a lifelong condition," she says, using the term interchangeably with PCOS (19:17). The insulin resistance and metabolic risk continue after ovulation stops, which means A1C, lipid panels, and blood pressure still need monitoring in menopause. The gap in care is stark: 10 to 20 percent of women have PCOS, yet there are zero FDA-approved medications for the condition itself (20:13). GLP-1 drugs, a class including semaglutide used for weight loss and blood sugar control, are helping some patients, though Haydanek tells those trying to conceive to stop them two months before attempting pregnancy, since safety in pregnancy has not been established (21:28).

Haver also walks through the Menopause Society's 2023 non-hormone position statement, which lists cognitive behavioral therapy, SSRIs, gabapentin, Veozah, and weight loss as supported options for hot flashes, and explicitly does not recommend exercise, yoga, dietary changes, or acupuncture for that purpose (22:06). Her read is not that those practices are worthless generally, but that a clinician who defaults to "try yoga" instead of naming hormone therapy as the gold standard may simply not know how to manage menopause, and should refer the patient to someone who does (24:41).

The Number Behind the Fear

No topic carries more inherited fear than the Women's Health Initiative, or WHI, a large federal study from the early 2000s that shaped two decades of hormone therapy practice. Haver breaks down what it actually found: in the arm combining estrogen and a synthetic progestin, there were about nine extra breast cancer cases per 10,000 women per year compared with placebo, a difference that approached but did not reach statistical significance, with no difference in breast cancer mortality (28:41). In the estrogen-only arm, given to women without a uterus, breast cancer incidence was actually lower than placebo, 30 cases versus 37 per 10,000 (29:00). Haver, who was a chief resident when the study broke in 2002, has watched the fallout split along generational lines: younger patients, without the historical memory, tend to be more open to hormone therapy, while older patients who were pulled off medication decades ago are often angry.

I would be upset, too, if I was on a medication that really helped me and then my doctor told me, "You're gonna get cancer and you have to stop," and then 20 years later I'm still suffering.
— Dr. Fran Haydanek (30:16)

Her counseling approach is to replace a vague warning with the actual numbers, so a patient can weigh a small, specific risk against a daily quality of life she understands.

The conversation closes on a place where Haydanek thinks the internet got something right: pain during IUD insertions and endometrial biopsies. She traces part of the problem to history, IUDs were first studied mostly in women who had recently given birth, whose cervixes tolerate the procedure differently than those who have not (32:56). When patients without that history reported severe pain, Haydanek says, they were often not believed. Social media changed that, pushing ACOG, the American College of Obstetricians and Gynecologists, to finally issue pain management guidance only in the last year or two (34:18). Haydanek learned techniques like the paracervical block, a numbing injection around the cervix, from watching other physicians online rather than from her own residency training, where pain management for these procedures was simply not discussed (35:19). It is a small, specific example of a larger theme running through the hour: patients describing their own bodies loudly enough, for long enough, to change what medicine is willing to treat as real.